Most chronic obstructive pulmonary disease (COPD) exacerbations were observed in those not treated with controller medications, but less than half of patients in the study received controller ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. COPD exacerbations went down by 51% in patients with ...
Healio Pulmonology has compiled the top news on COPD posted in 2025.Readers were most interested in how pulmonary ...
According to a recent study, patients with an exacerbation of chronic obstructive pulmonary disease (COPD) have greater risks of both subsequent exacerbations and mortality. The odds of subsequent ...
—A new study finds that some patients are proactive (they seek immediate treatment), while others tough it out (wishing to avoid the ‘hassle’ or ‘inconvenience’). What can clinicians do to better ...
Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...
New trial analysis shows COPD treatment withdrawal, including LAMA and ICS discontinuation, can trigger early exacerbation ...
Researchers found that the risk for moderate or severe COPD exacerbation was lower among those treated with SGLT-2is vs DPP-4is and among those treated with GLP-1 RAs vs DPP-4is. HealthDay News — For ...
Paris and Tarrytown, N.Y. November 27, 2023. The second Dupixent® (dupilumab) investigational Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) has shown that Dupixent significantly ...
Lower levels of serum sclerostin (SOST) were significantly associated with increased risk of lung exacerbations and hospitalizations in adults with chronic obstructive pulmonary disease (COPD), based ...
Credit: Getty Images. Ensifentrine (RPL554) is a first-in-class, dual phosphodiesterase (PDE) 3 and 4 inhibitor with combined bronchodilator and anti-inflammatory actions. Treatment with nebulized ...
Clinical guidelines recommend use of exacerbation history in choosing therapies to predict the risk for chronic obstructive pulmonary disease exacerbations, but an analysis of data from three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback